Aqemia
Business Services · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1 Boulevard Pasteur, Paris, Ile-de-Franc...Website
www.aqemia.comRevenue
$12.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
1
1
About Aqemia
AQEMIA is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. The company's mission is to design fast innovative drug candidates for dozens of critical diseases. The company's differentiation lies in the company's unique quantum and statistical mechanics algorithms fueling a generative artificial intelligence to design novel drug candidates, with already several drug discovery successes in internal pipeline as well as in collaboration with Pharma companies.Explore more
Aqemia Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aqemia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Aqemia launches new products
Funding: Get notified immidiatlly once Aqemia has new funding data
Earning: See what the market has to say on Aqemia recently announced quarterly report
Check if Aqemia has recently received funding, and reach out quickly before it becomes old news!
Click to see if Aqemia had a recent Job posting/layoffs
Check out if Aqemia is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Aqemia
Aqemia, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Aqemia as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Aqemia is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Aqemia is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Aqemia.
Aqemia financials insights
Gather financial insights about Aqemia, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series A
$65M
Other Financing Round
$38M
Aqemia Tech Stack
A closer look at the technologies used by Aqemia
Most Recent Scoops
Hiring Plans
Aqemia has more open roles in Engineering & Technical than it has had at any time in the past 12 months. Technologies mentioned include: SQL, Python, Snowflake, JavaScript, NoSQL, Github, and Fortran. Areas of expertise include: Computing Platforms, Scalability, Software Testing, System Optimization, AWS Tools, Custom Backend, and Cloud Infrastructure.
Hiring Plans
Open Position
Hiring Plans
Aqemia has more open roles in Engineering & Technical than it has had at any time in the past 12 months. Technologies mentioned include: Python, SQL, Snowflake, JavaScript, NoSQL, and Github.
Hiring Plans
Open Position
Hiring Plans
Hiring Plans
Aqemia News & Media
Follow the Money: Teaching AI Physics, AI-Powered Digital Twins of Cells, More
Stay on top of emerging IT trends in biomedicine. Read the latest news on genomics, computational science, and more. Get recent updates today!AQEMIA Hits $100 Million Funding Milestone, Paving Way to Clinical Trials and Global Expansion Starting with London, UK
PARIS & LONDON--(BUSINESS WIRE)-- #DrugDiscovery--AQEMIA, a pioneering techbio that teaches atomic scale physics to a generative AI to invent innovative medicines, announces two major milestones: $100 million in cumulative funding and the beginning of a global expansion starting with London (United Kingdom). The new $38 million funding round, led by new investor Cathay Innovation, brings total funds raised since inception to over $100 million. This round, coming less than a year after the previoAQEMIA Achieves Research Milestone Against Undruggable Target in Immuno-Oncology with Servier
PARIS--(BUSINESS WIRE)--AQEMIA, a leading company in generative-AI-driven drug discovery, announces the achievement of a research milestone in its collaboration with Servier, an international independent pharmaceutical company, to address an undruggable target in immuno-oncology. Based on AQEMIA ‘s quantum and statistical physics-based calculations, and within the span of a few months, a series of molecules experimentally active on an undruggable target in immuno-oncology have been successfullyAqemia Raises Additional €30M in Series A
Aqemia, a Paris, France-based tech-enabled drug discovery company, raised additional €30M in Series A funding. The round, which brought the total amount to €60M, was led by Wendel Growth with participation from Bpifrance Large Venture, Eurazeo, and Elaia. The company intends to use the funds to accelerate the growth of its wholly-owned pipeline of drug […] The post Aqemia Raises Additional €30M in Series A appeared first on FinSMEs.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aqemia
Sign Up For FreeTo access detailed company insights
AQEMIA is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. The company's mission is to design fast innovative drug candidates for dozens of critical diseases. The company's differentiation lies in the company's unique quantum and statistical mechanics algorithms fueling a generative artificial int... Read More
